Arcus Biosciences, Inc.
NYSE:RCUS
16.46 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 127 | 206 | 147.914 | 173.415 | 57.937 | 71.064 | 98.426 | 65.16 |
| Short Term Investments
| 632 | 803 | 351.394 | 555.231 | 130.333 | 185.48 | 77.277 | 33.736 |
| Cash and Short Term Investments
| 759 | 1,138 | 681.298 | 735.086 | 188.27 | 256.544 | 175.703 | 98.896 |
| Net Receivables
| 42 | 43 | 746.822 | 1.698 | 0.132 | 0.083 | 0.025 | 0.405 |
| Inventory
| 0 | -172 | -762.442 | -7.169 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 30 | 58 | 15.62 | 5.471 | 4.303 | 2.321 | 1.141 | 0.39 |
| Total Current Assets
| 831 | 1,067 | 681.298 | 735.086 | 192.705 | 258.948 | 176.869 | 99.691 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 51 | 35 | 137.423 | 23.588 | 9.33 | 11.107 | 11.23 | 8.608 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 107 | 129 | 181.99 | 6.44 | 0.203 | 4.383 | 0.682 | 1 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 106 | 114 | 591.187 | 7.178 | 0.872 | 0.487 | 1.705 | 0.403 |
| Total Non-Current Assets
| 264 | 278 | 910.6 | 37.206 | 10.405 | 15.977 | 13.617 | 10.011 |
| Total Assets
| 1,095 | 1,345 | 1,591.898 | 772.292 | 203.11 | 274.925 | 190.486 | 109.702 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 17 | 20 | 10.261 | 15.682 | 4.704 | 3.102 | 3.82 | 3.867 |
| Short Term Debt
| 11 | 3 | 53.768 | 27.85 | 9.522 | 6.023 | 3.137 | 0 |
| Tax Payables
| 0 | 0 | 1.815 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 91 | 97 | 102.003 | 74.571 | 7 | 6.25 | 5 | 0 |
| Other Current Liabilities
| 65 | 73 | 0.052 | 3.566 | 1.48 | 1.56 | 0.769 | 1.679 |
| Total Current Liabilities
| 184 | 193 | 166.084 | 121.669 | 22.706 | 16.935 | 12.726 | 5.546 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 110 | 117 | 116.887 | 15.243 | 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 307 | 355 | 462.217 | 122.83 | 12.022 | 16.984 | 18.587 | 0 |
| Deferred Tax Liabilities Non-Current
| -110 | -117 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 142 | 140 | 5.26 | 10.246 | 4.54 | 6.064 | 5.305 | 4.696 |
| Total Non-Current Liabilities
| 449 | 495 | 584.364 | 148.319 | 16.562 | 23.048 | 23.892 | 4.696 |
| Total Liabilities
| 633 | 688 | 750.448 | 269.988 | 39.268 | 39.983 | 36.618 | 10.242 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 274.925 | 226.196 | 119.454 |
| Common Stock
| 1,311 | 1,206 | 0.007 | 0.006 | 0.004 | 0.004 | 0.003 | 0.001 |
| Retained Earnings
| -849 | -542 | -275.354 | -328.184 | -205.326 | -122.828 | -73.234 | -20.152 |
| Accumulated Other Comprehensive Income/Loss
| 0 | -7 | -1.261 | 0.044 | 0.064 | -0.107 | -0.042 | -0.026 |
| Other Total Stockholders Equity
| 0 | 0 | 1,118.058 | 830.438 | 369.1 | 82.948 | 0.945 | 0.183 |
| Total Shareholders Equity
| 462 | 657 | 841.45 | 502.304 | 163.842 | 234.942 | 153.868 | 99.46 |
| Total Equity
| 462 | 657 | 841.45 | 502.304 | 163.842 | 234.942 | 153.868 | 99.46 |
| Total Liabilities & Shareholders Equity
| 1,095 | 1,345 | 1,591.898 | 772.292 | 203.11 | 274.925 | 190.486 | 109.702 |